Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 368
Filtrar
1.
Angiol Sosud Khir ; 25(4): 102-107, 2019.
Artigo em Russo | MEDLINE | ID: mdl-31855206

RESUMO

AIM: The purpose of the study was to assess efficacy and safety of heparin sodium gel 1000 IU/g and Detragel® in decreasing the incidence and treatment of the most common local adverse reactions in patients after endured sclerotherapy of reticular veins and telangiectasias. PATIENTS AND METHODS: Our open prospective observational study included a total of sixty 18-to-35-year-old female patients who after undergoing standardized sclerotherapy of reticular veins and telangiectasias on symmetrical portions of lower limbs were given a tube of heparin sodium gel 1000 IU/g or Detragel® to be applied onto the skin of one (left) lower limb in the projection of the sclerotherapy-exposed vessels 2-3 times daily for 10 days followed by putting on a compression class 2 (RAL standard) stocking. The women were allowed to use only the paired stocking on the contralateral extremity. Efficacy and safety of heparin sodium gel 1000 IU/g and Detragel® were evaluated based on the incidence of typical adverse reactions (ecchymoses, phlebitides, hyperpigmentation and neovasculogenesis), as well as on the patient's subjective perceptions. RESULTS: The use of heparin sodium gel 1000 IU/g and Detragel® in addition to compression after sclerotherapy of reticular veins and telangiectasias significantly and comparably decreased the incidence and accelerated the resolution of ecchymoses and phlebitides associated with phlebosclerosing treatment. The Detragel® group patients were found to develop hyperpigmentation or neovasculogenesis significantly less often as compared with the heparin sodium gel 1000 IU/g group women. What is more, using Detragel® was not accompanied by hyperkeratosis, pruritus or formation of a sticky film, the events, however, observed while applying heparin sodium gel 1000 IU/g. CONCLUSION: The use of Detragel® or heparin sodium gel 1000 IU/g for 10 days additionally to compression significantly decreased the incidence of typical undesirable reactions associated with sclerotherapy of reticular veins and telangiectasias. The Detragel® group women turned out to have lower incidence of hyperpigmentation and neovasculogenesis. Besides, Detragel® demonstrated better organoleptic properties.


Assuntos
Anticoagulantes/administração & dosagem , Heparina/administração & dosagem , Soluções Esclerosantes/efeitos adversos , Escleroterapia/efeitos adversos , Telangiectasia/terapia , Varizes/terapia , Administração Tópica , Feminino , Géis/administração & dosagem , Humanos , Hiperpigmentação/etiologia , Hiperpigmentação/prevenção & controle , Incidência , Neovascularização Patológica/etiologia , Neovascularização Patológica/prevenção & controle , Estudos Prospectivos , Meias de Compressão
2.
Actas dermo-sifiliogr. (Ed. impr.) ; 110(7): 533-545, sept. 2019. tab
Artigo em Espanhol | IBECS | ID: ibc-185525

RESUMO

Las últimas evidencias científicas y la incorporación de nuevos fármacos al arsenal terapéutico de la rosácea hacen necesario revisar y actualizar los criterios y estrategias de tratamiento. Con este fin, un grupo de 15 dermatólogos expertos en esta enfermedad aportaron y discutieron acerca de las diferentes terapias y los criterios de respuesta y cambio de tratamiento. Partiendo de la revisión crítica de la bibliografía y de la exposición de los hábitos de los dermatólogos españoles en su práctica clínica, se formularon distintas propuestas que fueron debatidas teniendo en consideración tanto la experiencia profesional como las preferencias de los pacientes o los criterios de equidad. Una vez validadas las propuestas, se formularon las recomendaciones finales que, junto con la evidencia aportada por las principales guías y estudios internacionales, dieron lugar al presente documento. El objetivo de este consenso es ofrecer al dermatólogo un enfoque práctico para abordar la rosácea


Recent scientific evidence and the incorporation of new drugs into the therapeutic arsenal against rosacea have made it necessary to review and update treatment criteria and strategies. To this end, a panel of 15 dermatologists, all experts in rosacea, was formed to share experiences and discuss treatment options, response criteria, and changes to treatment. Based on a critical review of the literature and a discussion of the routine practices of Spanish dermatologists, the panel proposed and debated different options, with consideration of the experience of professionals and the preferences of patients or equality criteria. Following validation of the proposals, the final recommendations were formulated and, together with the evidence from the main international guidelines and studies, used to produce this consensus document. The goal of this consensus document is to provide dermatologists with practical recommendations for the management of rosacea


Assuntos
Humanos , Consenso , Algoritmos , Rosácea/terapia , Rosácea/epidemiologia , Inquéritos e Questionários , Qualidade de Vida , Eritema/terapia , Telangiectasia/terapia , Administração Tópica , Técnica Delfos
4.
Dermatol Surg ; 45(7): 950-953, 2019 07.
Artigo em Inglês | MEDLINE | ID: mdl-30741789

RESUMO

BACKGROUND: Sclerotherapy is used to treat varicosities and telangiectases. Glycerin is a sclerosing agent that has been used off-label for years with a favorable adverse effect profile. However, the treatment of facial telangiectases with sclerotherapy is controversial given the potential for necrosis and embolization in relation to the complex vascular anatomy of the face. OBJECTIVE: To determine the safety and efficacy of glycerin sclerotherapy for the treatment of facial telangiectases. MATERIALS AND METHODS: The authors report a series of 8 patients with facial telangiectases treated with glycerin sclerotherapy. Glycerin mixed with lidocaine and epinephrine was used. The telangiectases were measured and identified as targets for treatment. RESULTS: The patients ranged in age from 45 to 88 years. Between 0.5 and 1 mL was used to treat telangiectases of the nose and malar cheek area per session. Five of the patients achieved satisfactory results after 1 treatment, whereas patients with more extensive telangiectases required up to 3 sessions with 4-week intervals between each session. Injection site pain was the only reported adverse effect, and no evidence of necrosis or blindness was observed. CONCLUSION: Glycerin sclerotherapy seems to be a safe and effective modality for the treatment of facial telangiectases.


Assuntos
Dermatoses Faciais/terapia , Glicerol/uso terapêutico , Soluções Esclerosantes/uso terapêutico , Escleroterapia , Telangiectasia/terapia , Idoso , Idoso de 80 Anos ou mais , Anestésicos Locais/uso terapêutico , Estudos de Coortes , Feminino , Humanos , Lidocaína/uso terapêutico , Masculino , Pessoa de Meia-Idade , Resultado do Tratamento
5.
J Am Acad Dermatol ; 80(6): 1722-1729.e7, 2019 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-30240779

RESUMO

Rosacea has been reported less frequently among individuals with skin of color than in those with white skin, but rosacea is not a rare disease in this population. In fact, rosacea might be underreported and underdiagnosed in populations with skin of color because of the difficulty of discerning erythema and telangiectasia in dark skin. The susceptibility of persons with highly pigmented skin to dermatologic conditions like rosacea, whose triggers include sun exposure, is probably underestimated. Many people with skin of color who have rosacea might experience delayed diagnosis, leading to inappropriate or inadequate treatment; greater morbidity; and uncontrolled, progressive disease with disfiguring manifestations, including phymatous rosacea. In this article, we review the epidemiology of rosacea in skin of color and highlight variations in the clinical presentation of rosacea across the diverse spectrum of patient populations affected. We present strategies to aid in the timely diagnosis and effective treatment of rosacea in patients with skin of color, with an aim of promoting increased awareness of rosacea in these patients and reducing disparities in the management of their disease.


Assuntos
Rosácea/epidemiologia , Pigmentação da Pele , Acne Vulgar/diagnóstico , Grupos de Populações Continentais , Diagnóstico Tardio , Dermatite/diagnóstico , Diagnóstico Diferencial , Eritema/etiologia , Rubor/etiologia , Saúde Global , Disparidades em Assistência à Saúde , Humanos , Anamnese , Prevalência , Rosácea/complicações , Rosácea/diagnóstico , Rosácea/fisiopatologia , Avaliação de Sintomas , Telangiectasia/etiologia , Telangiectasia/terapia
7.
J Cosmet Laser Ther ; 21(3): 163-165, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-30040520

RESUMO

Intense pulsed light (IPL) is a good option for erythema and telangiectasia of rosacea. Demodex, which is light and heat sensitive, is an important risk of Rosacea. Sometimes, IPL can induce rosacea aggravation. Here, we show two cases of erythema rosacea aggravated as pustule in several hours after IPL. Both cases show high density of Demodex after IPL. Neither of them had photosensitivity, systemic disease, or any other contraindication for IPL. One of the patients received IPL again after Demodex infection relieved and this time there was no inflammation induction. We need to attract more attention to IPL-induced rosacea aggravation and latent Demodex infection may act as a cofactor.


Assuntos
Eritema/terapia , Terapia de Luz Pulsada Intensa/efeitos adversos , Infestações por Ácaros/etiologia , Rosácea/terapia , Telangiectasia/terapia , Adulto , Animais , Antibacterianos/administração & dosagem , Antibacterianos/uso terapêutico , Biópsia , Feminino , Seguimentos , Humanos , Imunossupressores/administração & dosagem , Imunossupressores/uso terapêutico , Pessoa de Meia-Idade , Minociclina/administração & dosagem , Minociclina/uso terapêutico , Estudos Retrospectivos , Pele/patologia , Creme para a Pele/uso terapêutico , Tacrolimo/administração & dosagem , Tacrolimo/uso terapêutico , Resultado do Tratamento
8.
Angiol Sosud Khir ; 24(3): 92-97, 2018.
Artigo em Russo | MEDLINE | ID: mdl-30321152

RESUMO

Compression serves as an important component for carrying out successful and safe phlebosclerosing treatment. At the same time, the necessity of wearing compression hosiery or bandages is associated with known limitations and objections of patients, especially in a hot season. We comparatively assessed efficacy of usual compression stockings and a short-term pneumatic bandage with cryoelements while carrying out sclerosing treatment of dilated intradermal veins. Our open prospective observational study included a total of fifty 18-to-35-year-old women. After performing standardized sclerotherapy of reticular veins and telangiectasias on the symmetrical portions of the lower limbs, a pneumatic cryocompression bandage with a pressure of 50 mmHg was applied onto one of the limbs for 15 minutes, with a class 2 compression (RAL standard) medical stocking put on the other limb to be worn by the patients at daytime for 10 days. We assessed completeness of obliteration of the target veins, frequency of the development of typical undesirable events (ecchymoses, phlebitides, hyperpigmentation and neovasculogenesis), as well as the composite discomfort score according to an 11-point visual analogue scale. It was determined that using the pneumatic bandage with cryoelements as compared with the traditional compression stockings significantly decreased the frequency of the development of typical undesirable events after phlebosclerosing treatment, such as formation of ecchymoses, phlebitides, hyperpigmentation and neovasculogenesis. Significance of differences was revealed as early as 7 days after sclerotherapy, to be increasing during further dynamic follow up. By convenience for the patients, the use of the short-term pneumatic cryobandage was four times better than wearing the compression stockings. A conclusion was drawn that while carrying out sclerotherapy of reticular veins and telangiectasias short-term pneumatic cryocompression by efficacy and safety was not inferior to the traditional medical stockings (RAL standard) and made it possible to significantly decrease the incidence of the known undesirable events after phlebosclerosing treatment.


Assuntos
Crioterapia/métodos , Extremidade Inferior/irrigação sanguínea , Escleroterapia , Meias de Compressão , Telangiectasia/terapia , Varizes/terapia , Adulto , Pesquisa Comparativa da Efetividade , Feminino , Humanos , Projetos Piloto , Escleroterapia/instrumentação , Escleroterapia/métodos , Telangiectasia/diagnóstico , Varizes/diagnóstico , Escala Visual Analógica
9.
J Cosmet Dermatol ; 17(5): 779-782, 2018 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-30226025

RESUMO

BACKGROUND: Heat modalities are commonly used as either primary or adjunctive treatment for telangiectasia. Minimal information is available as to the nature of injury to the vessel and surrounding tissue. METHOD: A total of 135 patients were treated over a 2-year period using ohmic thermolysis (45), 940 nm laser (50), and 940 nm laser with sclerotherapy (40). After treatment, 1 mm biopsies were done in selected patients in each group. Clinical correlation was studied in each group by observing vessel response at 4-6 weeks postprocedure. RESULTS: Ohmic thermolysis produces electrodessication of the squamous epithelium, reticular dermis, and fusion of the target vessel. 940 nm laser results include squamous epithelial damage, subcutaneous water blister, collagen denaturation, and vessel endothelial cell loss with thrombus at point of maximal impact. The addition of sclerotherapy at time of laser potentiates vessel damage. There was no long-term skin sequelae after treatment when each device is used at recommended settings and on appropriate vessel size. CONCLUSION: Each device causes damage to the squamous epithelium and papillary reticular dermis that is transient. Ohmic thermolysis provides vessel clearance of >90% in telangiectasias <0.5 mm. 940 nm laser effectiveness is <70% for vessel clearance, but improves to >90% when sclerotherapy is performed at time of treatment.


Assuntos
Eletrocoagulação/métodos , Fotocoagulação a Laser/métodos , Terapia por Radiofrequência/métodos , Telangiectasia/patologia , Telangiectasia/terapia , Humanos , Escleroterapia , Pele/patologia
10.
Clin Lymphoma Myeloma Leuk ; 18(11): 724-730, 2018 11.
Artigo em Inglês | MEDLINE | ID: mdl-30100329

RESUMO

TEMPI (telangiectasias, erythrocytosis with elevated erythropoietin, monoclonal gammopathy, perinephric fluid collections, intrapulmonary shunting) syndrome is a newly described clinical entity that is generally considered a plasma cell dyscrasia with multiple system involvement. The etiology and pathophysiology of this condition remains elusive. Nevertheless, clonal plasma cells and monoclonal protein appear to be major contributors. The early diagnosis of TEMPI syndrome is essential because therapies targeting the underlying plasma cells can lead to a dramatic response. Bortezomib-based chemotherapy, daratumumab monotherapy, and autologous hematopoietic stem cell transplantation can result in reversal of most manifestations. Nevertheless, the diagnosis of TEMPI syndrome remains a substantial challenge owing to its rarity and the complexity of clinical presentations. TEMPI syndrome is often misdiagnosed as other causes of erythrocytosis, resulting in a delayed diagnosis and further clinical deterioration. The aim of the present review was to present the clinical and biologic features of TEMPI syndrome, highlighting the differential diagnosis and outlining the present understanding of its pathophysiology and treatment.


Assuntos
Neoplasias de Plasmócitos/patologia , Paraproteinemias/patologia , Policitemia/patologia , Telangiectasia/patologia , Transplante de Células-Tronco Hematopoéticas , Humanos , Neoplasias de Plasmócitos/complicações , Neoplasias de Plasmócitos/terapia , Paraproteinemias/complicações , Paraproteinemias/terapia , Policitemia/complicações , Policitemia/terapia , Prognóstico , Síndrome , Telangiectasia/complicações , Telangiectasia/terapia , Transplante Autólogo
11.
Skinmed ; 16(3): 199-200, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-29989542

RESUMO

A 78-year-old woman with a history of bilateral hip replacements presented with an ill-defined erythematous plaque with foci of reticulated and indurated areas on the left thigh. Initially, a few weeks after her surgery, a small area of erythema appeared overlying the incision site. Over a 6-month period, the erythema slowly expanded before stabilizing in size (Figure 1). There was no pruritus, pain, or warmth. Orthopedic evaluation found no evidence of infection or malfunction of the hip prosthesis. A skin biopsy revealed telangiectasia of the superficial vessels. Based on the clinical and histopathologic findings, a diagnosis of reticular telangiectatic erythema (RTE) was established. An ultrasound scan revealed a greater trochanteric bursa distended by a chronic, organized hematoma measuring 12 cm at greatest dimension, secondary to a full-thickness tear of the left gluteus minimus (Figure 2), establishing the underlying cause of the RTE in this patient.


Assuntos
Artroplastia de Quadril/efeitos adversos , Eritema/etiologia , Hematoma/etiologia , Complicações Pós-Operatórias/etiologia , Telangiectasia/etiologia , Idoso , Doença Crônica , Eritema/diagnóstico , Eritema/terapia , Feminino , Hematoma/diagnóstico , Hematoma/terapia , Humanos , Complicações Pós-Operatórias/diagnóstico , Complicações Pós-Operatórias/terapia , Telangiectasia/diagnóstico , Telangiectasia/terapia
12.
Clin Dermatol ; 36(4): 459-474, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-30047430

RESUMO

Systemic sclerosis is an uncommon autoimmune connective tissue disease with multiorgan system involvement and significant associated morbidity and mortality. Cutaneous signs and clinical manifestations are of particular importance, as they may be recognized before systemic manifestations, allowing earlier risk stratification into the limited and diffuse cutaneous subtypes, as well as earlier initiation of treatment. Important cutaneous manifestations include Raynaud's phenomenon, digital ulcers, cutaneous sclerosis, calcinosis cutis, telangiectasias, pruritus, and dyspigmentation. Despite investigation of a wide variety of treatments, no FDA-approved pharmacologic therapies exist for systemic sclerosis, and data from high-quality studies are limited. In the following review, we will discuss skin-directed therapies. Although there is evidence to support specific treatments for Raynaud's phenomenon, digital ulcers, and cutaneous sclerosis, there are limited rigorous studies evaluating the treatment of other cutaneous signs and clinical manifestations. Additional randomized-controlled trials and large observational studies are necessary to develop future evidence-based treatment options.


Assuntos
Esclerodermia Localizada/terapia , Escleroderma Sistêmico/complicações , Escleroderma Sistêmico/terapia , Autoanticorpos/sangue , Calcinose/etiologia , Calcinose/terapia , Dedos , Humanos , Transtornos da Pigmentação/tratamento farmacológico , Transtornos da Pigmentação/etiologia , Prurido/tratamento farmacológico , Prurido/etiologia , Doença de Raynaud/etiologia , Doença de Raynaud/terapia , Esclerodermia Localizada/etiologia , Escleroderma Sistêmico/classificação , Úlcera Cutânea/etiologia , Úlcera Cutânea/terapia , Telangiectasia/etiologia , Telangiectasia/terapia , Terminologia como Assunto
13.
Adv Ther ; 35(7): 1001-1008, 2018 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-29949043

RESUMO

INTRODUCTION: Sclerotherapy is a common technique for the removal of intradermal veins. This study examined the rationale for prescribing micronized purified flavonoid fraction (MPFF) in clinical, etiological, anatomic, pathophysiologic (CEAP) class C1 patients with dilated intradermal veins scheduled for sclerotherapy. METHODS: In a national, multicenter, observational program, physicians recruited CEAP C1s patients scheduled for sclerotherapy. The decision to prescribe adjuvant MPFF (1000 mg/day for 6 weeks beginning 2 weeks before sclerotherapy) was made according to usual practice. Disease severity and treatment outcomes were assessed at baseline and 4 weeks post-sclerotherapy using a visual analog scale (VAS) as well as quality-of-life (CIVIQ-14) and patient satisfaction (Darvall) questionnaires. RESULTS: A total of 70 physicians recruited 1150 patients: 1071 (93%) women, 79 (7%) men. Mean age (± SD) was 40.7 ± 10.7 years (range 18-74) and mean body mass index was 23.6 ± 3.3 kg/m2. Reticular veins were observed in 42.1% of patients and 57.9% had telangiectasias. MPPF was prescribed to 905 patients (79%). Sclerotherapy was associated with statistically significant decreases in mean VAS scores for leg heaviness, pain, sensation of swelling, night cramps, and itching. For each symptom, MPFF-treated patients showed a more pronounced improvement than those undergoing sclerotherapy alone: mean VAS pain score with MPFF decreased from 1.90 ± 2.30 to 0.30 ± 0.62 versus 1.72 ± 1.93 to 0.52 ± 0.99 with sclerotherapy alone; mean VAS leg heaviness score with MPFF decreased from 2.80 ± 2.43 to 0.47 ± 1.07 versus 2.38 ± 2.23 to 0.76 ± 0.85 with sclerotherapy alone. Patient quality-of-life indicators improved with symptom resolution, particularly pain, and for each indicator the observed improvement was greater with MPFF. The outcomes of treatment exceeded patient expectations. Fewer patients experienced sclerotherapy-induced hyperpigmentation with adjunctive MPFF versus sclerotherapy alone (33.9% versus 41.2%, respectively, P = 0.034). No adverse events related to MPFF were observed. CONCLUSION: Resolution of venous symptoms post-sclerotherapy was greater in patients treated with MPFF compared with those undergoing sclerotherapy alone, supporting the rationale for use of MPFF in patients undergoing sclerotherapy. FUNDING: Servier.


Assuntos
Diosmina/administração & dosagem , Edema , Hesperidina/administração & dosagem , Dor , Qualidade de Vida , Escleroterapia , Telangiectasia/terapia , Administração Oral , Adulto , Doença Crônica , Combinação de Medicamentos , Edema/etiologia , Edema/prevenção & controle , Feminino , Flavonoides/administração & dosagem , Humanos , Masculino , Pessoa de Meia-Idade , Dor/etiologia , Dor/prevenção & controle , Profilaxia Pré-Exposição/métodos , Escleroterapia/efeitos adversos , Escleroterapia/métodos , Inquéritos e Questionários , Telangiectasia/diagnóstico , Resultado do Tratamento
14.
Angiol Sosud Khir ; 24(1): 102-106, 2018.
Artigo em Russo | MEDLINE | ID: mdl-29688201

RESUMO

Presented herein are the results of the observational follow up study programme dedicated to the assessment of appropriate use of adjuvant therapy with Detralex while carrying out phlebosclerosing treatment in patients suffering from dilated intradermal veins (clinical class C1 according to the CEAP classification). A conclusion was drawn that administration of Detralex for 60 days decreased the incidence rate of typical undesirable side events after phlebosclerosing therapy, thus making the use of this drug appropriate in routine clinical practice.


Assuntos
Diosmina/administração & dosagem , Hesperidina/administração & dosagem , Soluções Esclerosantes/efeitos adversos , Escleroterapia , Telangiectasia/terapia , Adulto , Combinação de Medicamentos , Feminino , Flavonoides/administração & dosagem , Humanos , Masculino , Pessoa de Meia-Idade , Substâncias Protetoras/administração & dosagem , Soluções Esclerosantes/administração & dosagem , Escleroterapia/efeitos adversos , Escleroterapia/métodos , Índice de Gravidade de Doença , Resultado do Tratamento
15.
Pediatr Dermatol ; 35(3): e186-e188, 2018 May.
Artigo em Inglês | MEDLINE | ID: mdl-29493003

RESUMO

A patient with extensive multisystem overgrowth caused by a somatic gain of function PIK3CA-mutation is described. This case is an example of the clinical diversity of the PIK3CA-Related Overgrowth Spectrum (PROS) as the patient had overlapping features of Congenital Lipomatous Overgrowth Vascular malformations Epidermal nevi and Skeletal abnormalities (CLOVES) syndrome and Megalencephaly-Capillary malformation Polymicrogyria (MCAP) syndrome and underlines the utility of this umbrella term.


Assuntos
Anormalidades Múltiplas/diagnóstico , Classe I de Fosfatidilinositol 3-Quinases/genética , Lipoma/diagnóstico , Megalencefalia/diagnóstico , Anormalidades Musculoesqueléticas/diagnóstico , Nevo/diagnóstico , Dermatopatias Vasculares/diagnóstico , Telangiectasia/congênito , Malformações Vasculares/diagnóstico , Anormalidades Múltiplas/genética , Anormalidades Múltiplas/terapia , Sequência de Bases , Broncodilatadores/uso terapêutico , Diagnóstico Diferencial , Nutrição Enteral , Humanos , Imunossupressores/uso terapêutico , Recém-Nascido , Lipoma/genética , Lipoma/terapia , Masculino , Megalencefalia/genética , Megalencefalia/terapia , Anormalidades Musculoesqueléticas/genética , Anormalidades Musculoesqueléticas/terapia , Mutação , Nevo/genética , Nevo/terapia , Fenótipo , Respiração Artificial/métodos , Sirolimo/uso terapêutico , Dermatopatias Vasculares/genética , Dermatopatias Vasculares/terapia , Telangiectasia/diagnóstico , Telangiectasia/genética , Telangiectasia/terapia , Malformações Vasculares/genética , Malformações Vasculares/terapia
16.
Surg Clin North Am ; 98(2): 415-429, 2018 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-29502781

RESUMO

Sclerotherapy has wide applicability in treating venous disease at every stage of clinical disease. The various sclerosant drugs and formulations each have unique properties, utilities, and side effects. Treating physicians should be aware of the differences between agents, accounting for disease presentation, vein characteristics, and patient comorbidities when selecting the appropriate sclerosing agents. Successful outcomes rely on proper patient evaluation and assessment for contraindications to sclerotherapy. Thorough patient education regarding realistic expectations with sclerotherapy in terms of symptoms relief, recurrence, and improvement in appearance is of chief importance.


Assuntos
Soluções Esclerosantes/uso terapêutico , Escleroterapia/métodos , Telangiectasia/terapia , Varizes/terapia , Formas de Dosagem , Humanos , Escleroterapia/efeitos adversos , Resultado do Tratamento , Varizes/diagnóstico
17.
J Cosmet Laser Ther ; 20(7-8): 436-441, 2018.
Artigo em Inglês | MEDLINE | ID: mdl-29452029

RESUMO

Intense pulsed light (IPL) has been used to treat postinflammatory hyperpigmentation and telangiectasia in Fitzpatrick type I -II skin. However, its therapeutic effects after superficial second-degree burns in Asian populations with Fitzpatrick type III-IV skin are uncertain. Thirty-five Han Chinese patients with facial or hand hyperpigmentation and telangiectasia due to second-degree fire burns received treatment with IPL. Each patient underwent 2-6 treatments over 3-5 weeks. The laser wavelength was 560-615 nm. Skin pigmentation was evaluated by two plastic surgeons as well as by the patients themselves (self-evaluation) before treatment at the end of the treatment cycle and 1 year after the first treatment. Blood flow in telangiectasia skin was measured by laser Doppler flow. The results showed that IPL significantly lessened hyperpigmentation so that close to normal skin color was achieved after the treatment cycles, and pigmentation did not reoccur 1 year after the first treatment. Approximately 82.9% of the patients were satisfied with their treatment outcomes. There were no post-treatment complications. Doppler showed a significant decreased blood flow in telangiectasia after treatment. In conclusion, IPL is an effective and safe modality for Chinese patients with hyperpigmentation and telangiectasia after fire burns.


Assuntos
Queimaduras/complicações , Hiperpigmentação/etiologia , Hiperpigmentação/terapia , Telangiectasia/etiologia , Telangiectasia/terapia , Adolescente , Adulto , Grupo com Ancestrais do Continente Asiático , China , Feminino , Humanos , Terapia de Luz Pulsada Intensa , Masculino , Pessoa de Meia-Idade , Satisfação do Paciente , Fluxo Sanguíneo Regional , Adulto Jovem
19.
Hautarzt ; 69(1): 5-9, 2018 Jan.
Artigo em Alemão | MEDLINE | ID: mdl-29302697

RESUMO

Radiation dermatitis (RD), an inflammatory skin disease that can be an unwanted side effect of medical radiation therapy (RT), most commonly occurs in patients undergoing cancer of the ENT, anal, and vulvar regions. The side effects on the skin and mucous membranes occur within a few weeks after the initiation of RT; however, late side effects can develop months to years after the RT. Therapeutically, various treatment approaches are considered such as pentoxifylline, hyperbaric oxygen therapy, laser therapy, and PBMT. In order to limit the reduced quality of life of patients with RT-induced fibrosis, supportive care consisting of pain therapy, psychological support, and wound care is necessary.


Assuntos
Terapia a Laser/métodos , Neoplasias/radioterapia , Fototerapia/métodos , Radiodermatite/terapia , Doença Crônica , Ensaios Clínicos como Assunto , Fibrose/terapia , Humanos , Terapia com Luz de Baixa Intensidade/métodos , Radiodermatite/classificação , Telangiectasia/terapia
20.
J Cosmet Laser Ther ; 20(3): 145-147, 2018 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-29020473

RESUMO

Cutis marmorata telangiectatica congenita is a rare disorder characterized by cutis marmorata, telangiectasia with or without recurrent ulcerations. It is a benign vascular anomaly with dilatation of capillaries and veins in the dermis. There is no satisfactory treatment for the ulcerative variety of cutis marmorata telangiectatica congenita. In this case, intense pulse light therapy was used with almost near total cure. Intense pulse light with its vascular filter of wavelength 550-1200 nm was used every fortnight till complete resolution of lesions.


Assuntos
Terapia de Luz Pulsada Intensa/métodos , Dermatopatias Vasculares/terapia , Telangiectasia/congênito , Feminino , Humanos , Telangiectasia/terapia , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA